Form D · Biotechnology
SONALASENSE, INC.
Oakland, CA · CIK 0001825955
Offering snapshot reported Nov 6, 2023 · SEC filing
- Reported sold
- $9.77M Offering amount: $15M
- Investors reported
- 30 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 21, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 6, 2023 | Initial | $9,765,000 | No comparison | 30 | SEC filing |
| Jan 10, 2022 | Initial | $20,093,202 | No comparison | 30 | SEC filing |
| Feb 11, 2021 | Initial | $3,933,400 | No comparison | 26 | SEC filing |
| Sep 30, 2020 | Initial | $999,980 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-496573
Source: Form D, filed Nov 6, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark P. De Souza | Director, Executive |
| Stuart Marcus | Director, Executive |
| Vincent Sai | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1111 Broadway Suite 2040
Oakland, CA, 94607
Oakland, CA, 94607